PARP Inhibitors in Prostate Cancer: A Promise Delivered

被引：2
|
作者：
Tripathi, Abhishek [1 ]
McFarland, Taylor [2 ]
Agarwal, Neeraj [2 ]
机构：
[1] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[2] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
来源：
EUROPEAN UROLOGY ONCOLOGY | 2020年 / 3卷 / 05期
关键词：
MUTATIONS;
D O I：
10.1016/j.euo.2020.08.006
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：612 / 614
页数：3
相关论文
共 50 条
  • [1] PARP inhibitors for prostate cancer
    Longoria, Ossian
    Beije, Nick
    de Bono, Johann S.
    SEMINARS IN ONCOLOGY, 2024, 51 (1-2) : 25 - 35
  • [2] PARP Inhibitors in Prostate Cancer
    Geethakumari, Praveen Ramakrishnan
    Schiewer, Matthew J.
    Knudsen, Karen E.
    Kelly, Wm. Kevin
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2017, 18 (06)
  • [3] Prostate cancer and PARP inhibitors: progress and challenges
    Teyssonneau, Diego
    Margot, Henri
    Cabart, Mathilde
    Anonnay, Mylene
    Sargos, Paul
    Vuong, Nam-Son
    Soubeyran, Isabelle
    Sevenet, Nicolas
    Roubaud, Guilhem
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2021, 14 (01)
  • [4] PARP inhibitors in ovarian cancer: Current status and future promise
    Liu, Joyce F.
    Konstantinopoulos, Panagiotis A.
    Matulonis, Ursula A.
    GYNECOLOGIC ONCOLOGY, 2014, 133 (02) : 362 - 369
  • [5] PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy
    Bhatia, Tejas
    Doshi, Gaurav
    Godad, Angel
    PATHOLOGY RESEARCH AND PRACTICE, 2024, 263 : 155617
  • [6] PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
    Congregado, Belen
    Rivero, Ines
    Osman, Ignacio
    Saez, Carmen
    Medina Lopez, Rafael
    BIOMEDICINES, 2022, 10 (06)
  • [7] Personalized medicine for metastatic prostate cancer: The paradigm of PARP inhibitors
    Maiorano, Brigida Anna
    Conteduca, Vincenza
    Catalano, Martina
    Antonuzzo, Lorenzo
    Maiello, Evaristo
    De Giorgi, Ugo
    Roviello, Giandomenico
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 192
  • [8] PARP inhibitors for homologous recombination-deficient prostate cancer
    Christenson, Eric S.
    Antonarakis, Emmanuel S.
    EXPERT OPINION ON EMERGING DRUGS, 2018, 23 (02) : 123 - 133
  • [9] PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review
    Ratta, Raffaele
    Guida, Annalisa
    Scotte, Florian
    Neuzillet, Yann
    Teillet, Asmahane Benmaziane
    Lebret, Thierry
    Beuzeboc, Philippe
    PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (04) : 549 - 560
  • [10] PARP Inhibitors in the Treatment of Prostate Cancer: From Scientific Rationale to Clinical Development
    Kwon, Whi-An
    WORLD JOURNAL OF MENS HEALTH, 2024, 42 (02) : 290 - 303
12345